Reviva Pharmaceuticals is a healthcare company committed to filling the gaps in the nervous system, cardiovascular, inflammatory, and metabolic diseases through the development of therapeutics. One of these is the RP5063 for the treatment of schizophrenia, which has passed Phase 2. In addition, there are also candidates for a product for the treatment of depression and obesity. The business is valued at $ 43.927M as today’s price climbed to $ 3.25, 10% more than the worth before the close of the last trading session. In the period from Tuesday to Thursday, the cost of RVPH dropped from $ 3.18 to a low of $ 2.68. The trading volume is surging every second.
The price jump has been boosted by the latest news of FDA approval. It has approved a Phase 3 clinical trial for drug candidate RP5063. The research will begin at the end of January this year. Schizophrenia affects around 1% of the world’s population, of which 3.5 million live only in the United States. This is a mental illness, accompanied by hallucinations, disturbances in the process of thinking and perception.